Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Acute Lymphoblastic Leukemia in the Older Adult.

Aldoss I, Forman SJ, Pullarkat V.

J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271.

PMID:
30763199
2.

Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones.

Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S.

Biol Blood Marrow Transplant. 2019 Jan 29. pii: S1083-8791(19)30083-7. doi: 10.1016/j.bbmt.2019.01.025. [Epub ahead of print]

PMID:
30708188
3.

Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.

Aldoss I, Khaled SK, Budde E, Stein AS.

Curr Oncol Rep. 2019 Jan 21;21(1):4. doi: 10.1007/s11912-019-0753-y. Review.

PMID:
30666425
4.

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V.

J Cell Physiol. 2019 Jan 8. doi: 10.1002/jcp.28091. [Epub ahead of print]

PMID:
30623427
5.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

6.

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

La Rosa C, Longmate J, Lingaraju CR, Zhou Q, Kaltcheva T, Hardwick N, Aldoss I, Nakamura R, Diamond DJ.

Biol Blood Marrow Transplant. 2018 Dec 16. pii: S1083-8791(18)30892-9. doi: 10.1016/j.bbmt.2018.12.070. [Epub ahead of print]

PMID:
30562587
7.

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.

Mei M, Aldoss I, Marcucci G, Pullarkat V.

Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.

PMID:
30499168
8.

Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?

Aldoss I, Pullarkat V.

Bone Marrow Transplant. 2019 Jan;54(1):3-5. doi: 10.1038/s41409-018-0398-8. Epub 2018 Nov 16. No abstract available.

PMID:
30446742
9.

Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.

Chen J, Ngo D, Aldoss I, Shayani S, Tsai NC, Pullarkat V.

Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1519811. [Epub ahead of print]

PMID:
30322332
10.

Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.

Aldoss I, Kamal MO, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2019 Feb;25(2):e41-e45. doi: 10.1016/j.bbmt.2018.09.041. Epub 2018 Oct 5.

PMID:
30292743
11.

The emerging story of acute lymphoblastic leukemia among the Latin American population - biological and clinical implications.

Quiroz E, Aldoss I, Pullarkat V, Rego E, Marcucci G, Douer D.

Blood Rev. 2019 Jan;33:98-105. doi: 10.1016/j.blre.2018.08.002. Epub 2018 Aug 14. Review.

PMID:
30126753
12.

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, Sanchez JF, Forman SJ, Ghobrial IM, Krishnan A.

Leukemia. 2019 Jan;33(1):266-270. doi: 10.1038/s41375-018-0213-y. Epub 2018 Jul 19.

PMID:
30026571
13.

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O'Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.

14.

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab.

Aldoss I, Song JY.

Blood. 2018 May 31;131(22):2507. doi: 10.1182/blood-2018-02-834911. No abstract available.

PMID:
29853461
15.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15. No abstract available.

16.

Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.

Burke PW, Aldoss I, Lunning MA, Devlin SM, Tallman MS, Pullarkat V, Mohrbacher AM, Douer D.

Leuk Res. 2018 Mar;66:49-56. doi: 10.1016/j.leukres.2017.12.013. Epub 2018 Jan 3.

PMID:
29407583
17.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

PMID:
29197676
18.

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.

Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, Hong H, Padeganeh A, Bedell V, Cao T, Khaled SK, Malki MMA, Salhotra A, Ali H, Aribi A, Palmer J, Aoun P, Spielberger R, Stein AS, Snyder D, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger D, Forman SJ, Pullarkat V, Marcucci G, Pillai R, Nakamura R.

Haematologica. 2017 Dec;102(12):2030-2038. doi: 10.3324/haematol.2017.172544. Epub 2017 Sep 29.

19.

Advances in adult acute lymphoblastic leukemia therapy.

Aldoss I, Stein AS.

Leuk Lymphoma. 2018 May;59(5):1033-1050. doi: 10.1080/10428194.2017.1354372. Epub 2017 Jul 26. Review.

PMID:
28745565
20.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

Mei MG, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869. doi: 10.1016/j.bbmt.2017.07.006. Epub 2017 Jul 18.

21.

Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.

Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O'Donnell M, Stein AS, Marcucci G, Forman S, Pullarkat V.

Am J Hematol. 2017 Sep;92(9):858-865. doi: 10.1002/ajh.24783. Epub 2017 Jun 5.

22.

Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.

Salhotra A, Shan Y, Tsai NC, Sanchez JF, Aldoss I, Ali H, Paris T, Spielberger R, Cao TM, Nademanee A, Forman SJ, Chen R.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1264-1268. doi: 10.1016/j.bbmt.2017.04.011. Epub 2017 Apr 18.

23.

Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

Hamilton BK, Rybicki L, Abounader D, Adekola K, Advani A, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers CR, Ganguly S, Jagasia M, Kennedy VE, Kim DDH, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner SB, Perales MA, Majhail NS.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1117-1121. doi: 10.1016/j.bbmt.2017.04.003. Epub 2017 Apr 7.

24.

Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.

Aldoss I, Song JY.

Blood. 2017 Mar 2;129(9):1231. doi: 10.1182/blood-2016-10-747550. No abstract available.

25.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J.

Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624. doi: 10.1016/j.bbmt.2017.01.067. Epub 2017 Jan 10.

26.

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Review.

PMID:
28028314
27.

Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.

Aldoss IT, Marcucci G, Pullarkat V.

Oncology (Williston Park). 2016 Dec 15;30(12):1080-91. Review.

28.

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG.

J Clin Oncol. 2017 Feb;35(4):394-401. doi: 10.1200/JCO.2016.69.0073. Epub 2016 Nov 21.

29.

Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.

Aldoss I, Stiller T, Song J, Al Malki M, Ali H, Salhotra A, Aribi A, Khaled S, Gaytan P, Murata-Collins J, Palmer J, Snyder D, O'Donnell M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Am J Hematol. 2017 Feb;92(2):E18-E19. doi: 10.1002/ajh.24604. No abstract available.

30.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG.

Nat Commun. 2016 Nov 8;7:13331. doi: 10.1038/ncomms13331.

31.

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva TI, Tsai W, Drake J, Carroll M, Wussow F, Chiuppesi F, Hardwick N, Dadwal S, Aldoss I, Nakamura R, Zaia JA, Diamond DJ.

Blood. 2017 Jan 5;129(1):114-125. doi: 10.1182/blood-2016-07-729756. Epub 2016 Oct 19.

32.

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults.

Lee KJ, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M.

Ther Clin Risk Manag. 2016 Aug 25;12:1301-10. doi: 10.2147/TCRM.S84261. eCollection 2016. Review.

33.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.

Al Malki MM, Aldoss I, Stiller T, Nakamura R, Snyder DS, Forman SJ, Pullarkat V.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):519-522. doi: 10.1016/j.clml.2016.06.005. Epub 2016 Jun 8.

PMID:
27394652
34.

Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Aldoss I, Gaal K, Al Malki MM, Ali H, Nakamura R, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1900-1903. doi: 10.1016/j.bbmt.2016.06.022. Epub 2016 Jun 23.

35.

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Aldoss I, Tsai NC, Slovak ML, Palmer J, Alvarnas J, Marcucci G, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1212-1217. doi: 10.1016/j.bbmt.2016.03.025. Epub 2016 Apr 1.

36.

Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.

Sikaria S, Aldoss I, Akhtari M.

Immunol Lett. 2016 Apr;172:113-23. doi: 10.1016/j.imlet.2016.02.014. Epub 2016 Feb 23. Review.

PMID:
26921100
37.

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O'Donnell M, Cai JL, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ.

Lancet Haematol. 2016 Feb;3(2):e87-98. doi: 10.1016/S2352-3026(15)00246-X. Epub 2015 Dec 24.

38.

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia.

Aldoss I, Al Malki MM, Stiller T, Cao T, Sanchez JF, Palmer J, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2016 Mar;22(3):575-8. doi: 10.1016/j.bbmt.2015.10.016. Epub 2015 Oct 19.

39.

Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.

Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V.

Eur J Haematol. 2016 Apr;96(4):375-80. doi: 10.1111/ejh.12600. Epub 2015 Jun 25.

PMID:
26095294
40.

Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Aldoss I, Stiller T, Cao TM, Palmer JM, Thomas SH, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1326-9. doi: 10.1016/j.bbmt.2015.03.021. Epub 2015 Apr 1.

41.

Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.

Aldoss I, Dagis A, Palmer J, Forman S, Pullarkat V.

Bone Marrow Transplant. 2015 May;50(5):746-8. doi: 10.1038/bmt.2015.8. Epub 2015 Mar 2. No abstract available.

PMID:
25730188
42.

Allogeneic hematopoietic cell transplantation in non-Hodgkin's lymphomas.

Aldoss I, Nademanee A.

Cancer Treat Res. 2015;165:329-44. doi: 10.1007/978-3-319-13150-4_14.

PMID:
25655617
43.

Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.

Pullarkat V, Aldoss I.

Crit Rev Oncol Hematol. 2015 Jul;95(1):38-45. doi: 10.1016/j.critrevonc.2015.01.005. Epub 2015 Jan 15. Review.

PMID:
25624175
44.

Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.

Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D.

Ann Hematol. 2014 Nov;93(11):1839-43. doi: 10.1007/s00277-014-2124-y. Epub 2014 Jun 7.

PMID:
24906216
45.

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

Douer D, Aldoss I, Lunning MA, Burke PW, Ramezani L, Mark L, Vrona J, Park JH, Tallman MS, Avramis VI, Pullarkat V, Mohrbacher AM.

J Clin Oncol. 2014 Mar 20;32(9):905-11. doi: 10.1200/JCO.2013.50.2708. Epub 2014 Feb 10.

PMID:
24516026
46.

Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non-Small Cell Lung Cancer: A Veterans' Affairs Central Cancer Registry (VACCR) Database Analysis.

Ganti AK, Gonsalves W, Loberiza FR Jr, Aldoss I, Batra R, Silberstein PT, Subbiah SP, Kessinger A.

Am J Clin Oncol. 2016 Apr;39(2):142-6. doi: 10.1097/COC.0000000000000040.

PMID:
24487419
47.

Nodular regenerative hyperplasia causing portal hypertension in a patient with chronic graft versus host disease: response to sirolimus.

Choe H, Aldoss I, Chaudhary P, Donovan J, Petrovic L, Pullarkat V.

Acta Haematol. 2014;132(1):49-52. doi: 10.1159/000356736. Epub 2014 Jan 15. Review. No abstract available.

PMID:
24434665
48.

The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.

Aldoss I, Ji L, Haider M, Pullarkat V.

Acta Haematol. 2014;131(4):202-7. doi: 10.1159/000354820. Epub 2013 Nov 27.

PMID:
24296475
49.

An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia.

Aldoss I, Pullarkat V, Patel R, Watkins K, Mohrbacher A, Levine AM, Douer D.

Med Oncol. 2013 Dec;30(4):744. doi: 10.1007/s12032-013-0744-z. Epub 2013 Oct 18.

PMID:
24135867
50.

Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?

Aldoss I, Pullarkat V.

Leuk Res. 2012 Dec;36(12):1547-51. doi: 10.1016/j.leukres.2012.09.008. Epub 2012 Sep 29. Review.

PMID:
23031555

Supplemental Content

Loading ...
Support Center